This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care ETFs: Elixir for Your Portfolio

On the other hand, if your arthritis or allergies are flaring up, the companies in the HealthShares Autoimmune-Inflammation ETF (HHA) want to sell you their treatment.

The new surgical products to fix cataracts have to be seen to be believed. Patients with 20/200 vision can be restored to near 20/20 vision with the insertion of artificial, custom fit lenses to replace the lens clouded by the cataract. The companies supplying these types of products are included in the 44.3% sector allocation of health care products in the HealthShares Ophthamology ETF (HHZ).

The one area of our economy where growth is virtually guaranteed is in the waist line. Obesity is rampant. Diabetes is becoming a risk at earlier and earlier ages.

I am personally waiting for a pill with no side effects that wipes out all my body fat so that I can eat as many strombolis and as much General Tso's chicken as I want. Some of the companies of the HealthShares Metabolic-Endocrine Disorders ETF (HHM) are working hard to help achieve this goal.

If a cure for obesity is not found anytime soon, the companies treating the side effects of obesity, such as asthma and heart disease, are positioned to benefit. These companies are grouped into the HealthShares Respitory/Pulmonary ETF (HHR) and the HealthShares Cardiology ETF (HRD).

By the way, if you choose to invest in any of these new ETFs and are asked about the lack of diversification, you can always say: "At least I have my health."

Kevin Baker became the senior financial analyst for TSC Ratings upon the August 2006 acquisition of Weiss Ratings by TheStreet.com, covering mutual funds. He joined the Weiss Group in 1997 as a banking and brokerage analyst. In 1999, he created the Weiss Group's first ratings to gauge the level of risk in U.S. equities. Baker received a B.S. degree in management from Rensselaer Polytechnic Institute and an M.B.A. with a finance specialization from Nova Southeastern University.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.70 0.00%
FB $78.81 0.00%
GOOG $540.78 0.00%
TSLA $230.51 0.00%
YHOO $42.04 0.00%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs